CNS-tumor treatment method and composition
A method, aerosol composition, and aerosolizing device for treating a brain tumor in a subject are disclosed. The method includes intranasally administering to the subject, an amount of a telomerase inhibitor, such as an oligonucleotide telomerase inhibitor, effective to inhibit growth of the tumor in the subject.
1. A method for treating a tumor of the central nervous system in a subject, comprising intranasally administering to the subject, an amount of an oligonucleotide telomerase inhibitor effective to inhibit growth of the tumor in the subject;
wherein the oligonucleotide telomerase inhibitor is 10-20 bases in length and comprises nuclease-resistant intersubunit linkages and an oligonucleotide sequence effective to bind by sequence-specific hybridization to the RNA component of human telomerase (hTR).
2. The method of claim 1 , which further includes administering to the subject, before, during, or following administration of the telomerase inhibitor, a second anti-tumor agent.
3. The method of claim 1 , wherein the telomerase inhibitor is effective to bind by sequence-specific hybridization to the template region of hTR.
4. The method of claim 3 , wherein the internucleoside linkages in the oligonucleotide are selected from N3′→P5′ phosphoramidate and N3′→P5′ thiophosphoramidate linkages.
5. The method of claim 3 , wherein the oligonucleotide includes the sequence identified by SEQ ID NO:12.
6. The method of claim 5 , wherein the internucleoside linkages in the oligonucleotide are selected from N3′→P5′ phosphoramidate and N3′→P5′ thiophosphoramidate linkages.
7. The method of claim 6 , wherein the telomerase inhibitor is the compound GRN163.
8. The method of claim 1 , which further includes selecting for treatment, a patient having a malignant glioma.